The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Department of Critical Care Medicine, Huizhou Municipal Central Hospital, 41 North E'ling Road, Huizhou, 516001, Guangdong, China.
BMC Anesthesiol. 2020 Nov 23;20(1):292. doi: 10.1186/s12871-020-01207-3.
It is not clear whether there are valuable inflammatory markers for prognosis judgment in the intensive care unit (ICU). We therefore conducted a multicenter, prospective, observational study to evaluate the prognostic role of inflammatory markers.
The clinical and laboratory data of patients at admission, including C-reactive protein (CRP), were collected in four general ICUs from September 1, 2018, to August 1, 2019. Multivariate logistic regression was used to identify factors independently associated with nonsurvival. The area under the receiver operating characteristic curve (AUC-ROC), net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were used to evaluate the effect size of different factors in predicting mortality during ICU stay. 3 -knots were used to assess whether alternative cut points for these biomarkers were more appropriate.
A total of 813 patients were recruited, among whom 121 patients (14.88%) died during the ICU stay. The AUC-ROC values of PCT and CRP for discriminating ICU mortality were 0.696 (95% confidence interval [CI], 0.650-0.743) and 0.684 (95% CI, 0.633-0.735), respectively. In the multivariable analysis, only APACHE II score (odds ratio, 1.166; 95% CI, 1.129-1.203; P = 0.000) and CRP concentration > 62.8 mg/L (odds ratio, 2.145; 95% CI, 1.343-3.427; P = 0.001), were significantly associated with an increased risk of ICU mortality. Moreover, the combination of APACHE II score and CRP > 62.8 mg/L significantly improved risk reclassification over the APACHE II score alone, with NRI (0.556) and IDI (0.013). Restricted cubic spline analysis confirmed that CRP concentration > 62.8 mg/L was the optimal cut-off value for differentiating between surviving and nonsurviving patients.
CRP markedly improved risk reclassification for prognosis prediction.
目前尚不清楚重症监护病房(ICU)中是否存在有价值的炎症标志物用于预后判断。因此,我们进行了一项多中心、前瞻性、观察性研究,以评估炎症标志物的预后作用。
2018 年 9 月 1 日至 2019 年 8 月 1 日,在四个普通 ICU 中收集了入院时患者的临床和实验室数据,包括 C 反应蛋白(CRP)。使用多变量逻辑回归确定与非生存独立相关的因素。采用受试者工作特征曲线下面积(AUC-ROC)、净重新分类改善(NRI)和综合判别改善(IDI)来评估不同因素在预测 ICU 期间死亡率方面的效果大小。使用 3 结来评估这些生物标志物的替代截断值是否更合适。
共纳入 813 例患者,其中 121 例(14.88%)在 ICU 期间死亡。PCT 和 CRP 预测 ICU 死亡率的 AUC-ROC 值分别为 0.696(95%置信区间 [CI],0.650-0.743)和 0.684(95% CI,0.633-0.735)。多变量分析中,只有 APACHE II 评分(比值比,1.166;95%CI,1.129-1.203;P = 0.000)和 CRP 浓度>62.8mg/L(比值比,2.145;95%CI,1.343-3.427;P = 0.001)与 ICU 死亡率增加显著相关。此外,APACHE II 评分与 CRP>62.8mg/L 的联合显著提高了 APACHE II 评分单独预测的风险再分类,NRI(0.556)和 IDI(0.013)。限制立方样条分析证实 CRP 浓度>62.8mg/L 是区分存活和非存活患者的最佳截断值。
CRP 显著改善了预后预测的风险再分类。